Structure-Function Analyses of New SARS-CoV-2 Variants B.1.1.7, B.1.351 and B.1.1.28.1: Clinical, Diagnostic, Therapeutic and Public Health Implications.
Structure-Function Analyses of New SARS-CoV-2 Variants B.1.1.7, B.1.351 and B.1.1.28.1: Clinical, Diagnostic, Therapeutic and Public Health Implications.
复制标题
DOI：
10.3390/v13030439
复制
发表时间：
2021-03-09
期刊：
影响因子：
--
通讯作者：
Hasnain SE
中科院分区：
文献类型：
--
作者：
Singh J;Samal J;Kumar V;Sharma J;Agrawal U;Ehtesham NZ;Sundar D;Rahman SA;Hira S;Hasnain SE
SARS-CoV-2(严重急性呼吸综合征-冠状病毒2)在全球传播过程中积累了多种变异。最近，英国、南非和巴西分别出现了三个SARS-CoV-2谱系，B.1.1.7(501Y.V1)，B.1.351(501Y.V2)和B.1.1.28.1(P.1)。在这里，我们提出了对新出现的SARS-CoV-2变异的影响的全球观点，基于其尖峰(S)、ORF8和核衣壳(N)蛋白发生的关键突变的结构-功能影响。虽然在所有三个家系中都观察到了N501Y突变，但501Y.V1和P.1在S蛋白中积累了一组不同的突变。通过新冠肺炎专用资源和原子分子动力学模拟预测错义突变效应。目前的研究结果表明，S蛋白的一些突变可能导致与宿主受体的高亲和力和对抗体的抵抗力，但并不是所有的突变都是由于不同的抗体结合(表位)区域所致。然而，突变可能会导致诊断测试失败，并可能干扰新发现的抗SARS-CoV-2候选病毒的结合，很可能需要每年推出反复出现的用于应对新冠肺炎的“流感疫苗”。这些突变的功能相关性已从调节宿主趋向性、抗体抵抗力、诊断敏感性和治疗候选方面进行了描述。除全球经济损失外，疫苗后再次感染新出现的变种可能会对临床、治疗和公共卫生产生重大影响。
SARS-CoV-2 (Severe Acute Respiratory Syndrome-Coronavirus 2) has accumulated multiple mutations during its global circulation. Recently, three SARS-CoV-2 lineages, B.1.1.7 (501Y.V1), B.1.351 (501Y.V2) and B.1.1.28.1 (P.1), have emerged in the United Kingdom, South Africa and Brazil, respectively. Here, we have presented global viewpoint on implications of emerging SARS-CoV-2 variants based on structural–function impact of crucial mutations occurring in its spike (S), ORF8 and nucleocapsid (N) proteins. While the N501Y mutation was observed in all three lineages, the 501Y.V1 and P.1 accumulated a different set of mutations in the S protein. The missense mutational effects were predicted through a COVID-19 dedicated resource followed by atomistic molecular dynamics simulations. Current findings indicate that some mutations in the S protein might lead to higher affinity with host receptors and resistance against antibodies, but not all are due to different antibody binding (epitope) regions. Mutations may, however, result in diagnostic tests failures and possible interference with binding of newly identified anti-viral candidates against SARS-CoV-2, likely necessitating roll out of recurring “flu-like shots” annually for tackling COVID-19. The functional relevance of these mutations has been described in terms of modulation of host tropism, antibody resistance, diagnostic sensitivity and therapeutic candidates. Besides global economic losses, post-vaccine reinfections with emerging variants can have significant clinical, therapeutic and public health impacts.
登录
查看更多内容
影响因子：
64.8
作者：
Barnes CO;Jette CA;Abernathy ME;Dam KA;Esswein SR;Gristick HB;Malyutin AG;Sharaf NG;Huey-Tubman KE;Lee YE;Robbiani DF;Nussenzweig MC;West AP Jr;Bjorkman PJ
通讯作者：
Bjorkman PJ
超越屏蔽：聚糖在SARS-COV-2尖峰蛋白中的作用。
影响因子：
18.2
作者：
Casalino L;Gaieb Z;Goldsmith JA;Hjorth CK;Dommer AC;Harbison AM;Fogarty CA;Barros EP;Taylor BC;McLellan JS;Fadda E;Amaro RE
通讯作者：
Amaro RE
DOI：
10.1126/science.abe8499
发表时间：
2020-12-18
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Hou YJ;Chiba S;Halfmann P;Ehre C;Kuroda M;Dinnon KH 3rd;Leist SR;Schäfer A;Nakajima N;Takahashi K;Lee RE;Mascenik TM;Graham R;Edwards CE;Tse LV;Okuda K;Markmann AJ;Bartelt L;de Silva A;Margolis DM;Boucher RC;Randell SH;Suzuki T;Gralinski LE;Kawaoka Y;Baric RS
通讯作者：
Baric RS
SARS-COV-2和382-NT缺失分离株缺乏ORF8的人类鼻上皮细胞的感染揭示了类似的病毒动力学和宿主的转录谱。
影响因子：
6.7
作者：
Gamage AM;Tan KS;Chan WOY;Liu J;Tan CW;Ong YK;Thong M;Andiappan AK;Anderson DE;Wang Y;Wang LF
通讯作者：
Wang LF
DOI：
10.1056/nejmoa2102214
发表时间：
2021-05-20
期刊：
The New England journal of medicine
影响因子：
--
作者：
Madhi SA;Baillie V;Cutland CL;Voysey M;Koen AL;Fairlie L;Padayachee SD;Dheda K;Barnabas SL;Bhorat QE;Briner C;Kwatra G;Ahmed K;Aley P;Bhikha S;Bhiman JN;Bhorat AE;du Plessis J;Esmail A;Groenewald M;Horne E;Hwa SH;Jose A;Lambe T;Laubscher M;Malahleha M;Masenya M;Masilela M;McKenzie S;Molapo K;Moultrie A;Oelofse S;Patel F;Pillay S;Rhead S;Rodel H;Rossouw L;Taoushanis C;Tegally H;Thombrayil A;van Eck S;Wibmer CK;Durham NM;Kelly EJ;Villafana TL;Gilbert S;Pollard AJ;de Oliveira T;Moore PL;Sigal A;Izu A;NGS-SA Group;Wits-VIDA COVID Group
通讯作者：
Wits-VIDA COVID Group